title: Continuity of care and desipramine in primary cocaine abusers.
abstract: The objective of this research was to determine the efficacy of enhanced continuity of care and desipramine in increasing treatment attendance and abstinence from cocaine in primary cocaine abusers. Study design was a random assignment, placebo-controlled factorial with assessments at baseline and at 3 (first week of outpatient treatment), 8, and 12 weeks after start of study. Desipramine blood levels were taken at weeks 2 (inpatient), 3, and 8. Subjects (N = 94 men) were recruited on an inpatient ward and assigned to increased continuity of care or to standard treatment, and to active or placebo drug. Main outcome variables were toxicology-verified reports of cocaine use, and attendance at counseling sessions. Enhanced continuity of care increased abstinence from cocaine at week 3 and increased attendance at individual counseling sessions throughout the 12 weeks of the study. There were no main effects for desipramine. Blood levels above 123 ng/ml at week 2 predicted longer stays in outpatient. We conclude that enhanced continuity of care is a low cost intervention that improves early treatment outcome and attendance; desipramine effects do not warrant its therapeutic use.
authors.affiliation: Department of Veterans Affairs Medical Center, San Francisco, California.
authors.forename: S M
authors.initials: SM
authors.lastname: Hall
authors.forename: S
authors.initials: S
authors.lastname: Tunis
authors.forename: E
authors.initials: E
authors.lastname: Triffleman
authors.forename: P
authors.initials: P
authors.lastname: Banys
authors.forename: H W
authors.initials: HW
authors.lastname: Clark
authors.forename: D
authors.initials: D
authors.lastname: Tusel
authors.forename: P
authors.initials: P
authors.lastname: Stewart
authors.forename: D
authors.initials: D
authors.lastname: Presti
mesh_terms: D000328:Adult; D000553:Ambulatory Care; D003042:Cocaine; D003266:Continuity of Patient Care / Q000191:economics; D003365:Costs and Cost Analysis; D003376:Counseling; D003891:Desipramine / Q000097:blood / Q000627:therapeutic use*; D005260:Female; D006760:Hospitalization; D006801:Humans; D007902:Length of Stay; D008297:Male; D010349:Patient Compliance; D010919:Placebos; D011336:Probability; D017064:Process Assessment, Health Care; D011613:Psychotherapy / Q000191:economics / Q000379:methods*; D011615:Psychotherapy, Group / Q000379:methods; D019966:Substance-Related Disorders / Q000188:drug therapy* / Q000534:rehabilitation; D016896:Treatment Outcome
chemical_list: D010919:Placebos; D003042:Cocaine; D003891:Desipramine